“Russian pharmaceutical manufacturers are currently actively developing drugs for the treatment of rare diseases ... Both drugs have shown high safety and effectiveness in preclinical animal trials,” the press release said.
The Ministry of Health also reported that in 2020, preclinical trials of the Russian gene therapy drug for the treatment of spinal muscular atrophy (SMA) are expected.
Earlier, the portal kp.ru wrote that in the Vladimir region they will direct 1.5 billion rubles to provide residents with preferential medicines in 2020.